Top stories in endocrinology — Liquid metformin available in US, CDC releases new diabetes report
Click Here to Manage Email Alerts
The FDA-approved liquid formulation of extended-release metformin is now available in the United States for patients who cannot swallow solid medications. It was the top story in endocrinology last week.
The CDC’s 2020 National Diabetes Statistics Report, which revealed that approximately 34.1 million U.S. adults have diabetes but 7.3 million were unaware or did not report having the disease, was another top story.
Read these and more news in endocrinology below:
Liquid metformin now available in US
The only FDA-approved liquid formulation of extended-release metformin is now available in the United States, according to a press release from Sun Pharma. Read more.
CDC: 13% of US adults have diabetes, with fewer new cases
Approximately 34.1 million U.S. adults — more than 1 in 10 —have type 1 or type 2 diabetes, and 7.3 million of those adults who met laboratory criteria were unaware or did not report having the disease, according to data from the CDC’s 2020 National Diabetes Statistics Report. Read more.
Hundreds of illegal Craigslist ads list insulin for sale
A recent report in JAMA Internal Medicine revealed that analogue insulins are the most commonly advertised prescription drugs on the online classified ad website Craigslist, with the drugs being offered at a fraction of their retail price. Read more.
FDA grants dulaglutide CV indication for diabetes with or without established CVD
The FDA approved the GLP-1 receptor agonist dulaglutide for the reduction of major adverse cardiovascular events for adults with type 2 diabetes who have established cardiovascular disease or multiple CV risk factors, making it the first type 2 diabetes drug approved for primary and secondary prevention populations, according to a press release from Eli Lilly. Read more.
Metabolic effects of glucocorticoids reversed with metformin
Adults with inflammatory disease prescribed glucocorticoid therapy experienced an improvement in several metabolic parameters after adding metformin therapy for 12 weeks compared with similar adults assigned placebo, according to findings from a phase 2 study published in The Lancet Diabetes & Endocrinology. Read more.